

Early next year, Northern Biologics will begin clinical testing of its lead immuno-oncology asset, MSC-01, in a range of cancers, working with world-leading cancer institutes in Canada, Europe and the U.S. MSC-01 is a humanized antibody against a soluble cytokine called LIF with the desired effects of blocking immunosuppression and inhibiting the self-renewal of cancer stem cells. In addition, the company's pipeline includes several antibodies acting on other relevant oncology

targets, including those within the TIGIT and the TIM-3 pathways.